Table 1 Baseline characteristics of total study population (intention-to-treat)
|  | Placebo (n = 57) | Quetiapine (n = 57) | All (n = 114) | P-Value |
|---|---|---|---|---|
Male, n (%) | 30 (52.6) | 32 (56.1) | 62 (54.4) | 0.707 |
Age, mean (SD) | 75.2 ± 6.9 | 75.4 ± 7.5 | 75.3 ± 7.1 | 0.835 |
  <  75, n (%) | 28 (49.1) | 26 (45.6) | 54 (47.4) | 0.708 |
  ≥ 75, n (%) | 29 (45.6) | 31 (54.4) | 60 (52.6) |  |
Body weight (kg), mean (SD) | 56.1 ± 10.4 | 55.7 ± 11.0 | 55.9 ± 10.6 | 0.851 |
BMI (kg/m2), mean (SD) | 22.56 ± 4.0 | 21.9 ± 3.8 | 22.2 ± 3.9 | 0.366 |
CCI score, median (IQR) | 2 (1, 3) | 2 (1, 3) | 2 (1, 3) | 0.584 |
Prehospital living, n (%) | Â | Â | Â | 0.079 |
 Home | 57 (100.0) | 54 (94.7) | 111 (97.4) |  |
 Home care | 0 (0.0) | 3 (5.3) | 3 (2.6) |  |
Mobility status, n (%) | Â | Â | Â | 0.050 |
 Independent | 42 (73.7) | 32 (56.1) | 74 (64.9) |  |
 Gait aids | 15 (26.3) | 25 (43.9) | 40 (35.1) |  |
Hearing aids, n (%) | 3 (5.3) | 3 (5.3) | 6 (5.3) | 1.000 |
Visual aids, n (%) | 31 (54.4) | 33 (57.9) | 64 (56.1) | 0.706 |
Smoking, n (%) | 9 (15.8) | 8 (14.0) | 17 (14.9) | 0.793 |
Alcohol, n (%) | 3 (5.3) | 4 (7.0) | 7 (6.1) | 0.927 |
Previous medication, n (%) | Â | Â | Â | 0.674 |
 Anticholinergics | 3 (5.3) | 5 (8.8) | 8 (7.0) |  |
 Antihistamines | 2 (3.5) | 1 (1.8) | 3 (2.6) |  |
 Benzodiazepines | 5 (8.8) | 5 (8.8) | 10 (8.8) |  |
 Opioids | 0 (0.0) | 2 (3.5) | 2 (1.8) |  |
Blood test results | Â | Â | Â | Â |
 Albumin, g/dL, median (IQR) | 29.9 (25.9, 34.5) | 30.3 (25.0, 34.9) | 30.1 (25.3,34.7) | 0.629 |
 Potassium, mmol/L, mean (SD) | 4.2 ± 0.5 | 4.2 ± 0.9 | 4.2 ± 0.7 | 0.751 |
 Creatinine, mg/dL, median (IQR) | 0.87 (0.74, 1.40) | 0.92 (0.68, 1.44) | 0.91 (0.72, 1.41) | 0.476 |
 eGFR, ml/min/1.73m2, median (IQR) | 73.1 (47.2, 88.6) | 72.5 (45.5, 86.4) | 72.6 (45.5, 88.2) | 0.571 |
Baseline QTc, ms, mean (SD) | 442.8 ± 30.5 | 446.2 ± 32.8 | 444.5 ± 31.6 | 0.562 |